Glial Cell Response: A Pathogenic Factor in Parkinson's Disease

References

• Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, Horwitz J, Ischiropoulos H (1998). Inactiva-tion of tyrosine hydroxylase by nitration following ex-posure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc Nati Acad Sci USA 95: 7659–7663.
   PubMed Web of Science ®Google Scholar
• Banati RB, Daniel SE, Blunt SB (1998). Glial pathol-ogy but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 13: 221–227.
   PubMed Web of Science ®Google Scholar
• Banati RB, Gehrmann J, Schubert P, Kreutzberg GW (1993). Cytotoxicity of microglia. Glia 7: 111–118.
   PubMed Web of Science ®Google Scholar
• Batchelor PE, Liberatore GT, Porritt MJ, Dolman GA, Howells DW (2000). Inhibition of brain-derived neu-rotrophic factor and glial cell line-derived neurotrophic factor expression reduces dopaminergic sprouting in the injured striatum. Eur J Neurosci 12: 3462–3468.
   PubMedGoogle Scholar
• Batchelor PE, Liberatore GT, Wong JY, Porritt MJ, Frerichs F, Donnan GA, Howells DW (1999). Acti-vated macrophages and microglia induce dopamin-ergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 19: 1708–1716.
   PubMed Web of Science ®Google Scholar
• Beal MF (2001). Experimental models of Parkinson's dis-ease. Nat Rev Neurosci 2: 325–334.
   PubMed Web of Science ®Google Scholar
• Benazzouz A, Piallat B, Ni ZG, Koudsie A, Pollak P, Benabid AL (2000). Implication of the subthalamic nucleus in the pathophysiology and pathogenesis of Parkinson's dis-ease. Cell Transplant 9: 215–221.
   Google Scholar
• Bessler H, Djaldetti R, Salman H, Bergman M, Djaldetti M (1999). IL-1 beta, IL-2, IL-6 and TNF-alpha produc-tion by peripheral blood mononuclear cells from pa-tients with Parkinson's disease. Biomed Pharmacother 53: 141–145.
   Google Scholar
• Brown H, Kozlowski R, Perry H (1998). The importance of ion channels for marcophage and microglial activation in vitro. Glia 22: 94–97.
   PubMedGoogle Scholar
• Burke RE, Antonelli M, Sulzer D (1998). Glial cell line-derived neurotrophic growth factor inhibits apop-totic death of postnatal substantia nigra dopamine neurons in primary culture. J Neurochem 71: 517–525.
   Google Scholar
• Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A (1996). Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5: 137–143.
   PubMedGoogle Scholar
• Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F (1993). Glutathione peroxidase, glial cells and Parkinson's dis-ease. Neuroscience 52: 1–6.
   PubMed Web of Science ®Google Scholar
• Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB (2000). Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 74: 2213–2216.
   PubMed Web of Science ®Google Scholar
• DeLong MR (1990). Primate models of movement disor-ders of basal ganglia origin. Trends Neurosci 13: 281–285.
   PubMed Web of Science ®Google Scholar
• Eberhardt O, Coelln RV, Kugler S, Lindenau J, Rathke-Hartlieb S, Gerhardt E, Haid S, Isenmann S, Gravel C, Srinivasan A, Bahr M, Weller M, Dichgans J, Schulz JB (2000). Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 20: 9126–9134.
   PubMed Web of Science ®Google Scholar
• Eddleston M, Mucke L (1993). Molecular profile of reactive astrocytes-implications for their role in neurologic dis-ease. Neuroscience 54: 15–36.
   PubMed Web of Science ®Google Scholar
• Fahn S (1989). Adverse effects of levodopa in Parkinson's disease. In: Handbook of experimental pharmacology, vol 8, Calne DB (ed). Springer-Verlag: Berlin, pp 386–409.
   Google Scholar
• Fahn S, Przedborski S (2000). Parkinsonism. In: Merritt's neurology. Rowland LP (ed). Lippincott Williams & Wilkins: New York, pp 679–693.
   Google Scholar
• Fomo LS, DeLanney LE, Irwin I, Di Monte D, Langston JW (1992). Astrocytes and Parkinson's disease. Prog Brain Res 94: 429–436.
   Google Scholar
• Fomo LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA (1986). Locus ceruleus lesions and eosinophilic inclu-sions in MPTP-treated monkeys. Ann Neurol 20: 449–455.
   Google Scholar
• Gash DM, Zhang ZM, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA (1996). Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252–255.
   PubMed Web of Science ®Google Scholar
• Gehrmann J, Banati RB, Kreutzberg GW (1993). Microglia in the immune surveillance of the brain: human microglia constitutively express HLA-DR molecules. J Neuroim-munol 48: 189–198.
   Google Scholar
• Gehrmann J, Matsumoto Y, Kreutzberg GW (1995). Microglia: intrinsic immuneffector cell of the brain. Brain Res Rev 20: 269–287.
   PubMed Web of Science ®Google Scholar
• Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000). Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopa-thy lesions. Science 290: 985–989.
   Google Scholar
• Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC (2000). Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Nail Acad Sci USA 97: 2875–2880.
   PubMed Web of Science ®Google Scholar
• Heikkila RE, Sieber BA, Manzino L, Sonsalla PK (1989). Some features of the nigrostriatal dopaminergic neu-rotoxin 1-methyl-4-phenyl-1,2, 3, 6-tetrahydropyridine (MPTP) in the mouse. Mol Chemic Neuropathol10: 171–183.
   Google Scholar
• Herrera AJ, Castano A, Venero JL, Cano J, Machado A (2000). The single intranigral injection of LPS as a new model for studying the selective effects of inflamma-tory reactions on dopaminergic system. Neurobiol Dis 7: 429–447.
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Hunot S, Damier P, Brugg B, Faucheux BA, Michel PP, Ruberg M, Muriel MP, Mouatt-Prigent A, Agid Y (1999). Glial cell participation in the degener-ation of dopaminergic neurons in Parkinson's disease. Adv Neurol 80: 9–18.
   PubMedGoogle Scholar
• Honykiewicz O, Kish SJ (1987). Biochemical pathophys-iology of Parkinson's disease. In: Parkinson's disease. Yahr M, Bergmann KJ (eds). Raven Press: New York, pp 19–34.
   Google Scholar
• Hunot S, Boissière F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC (1996). Nitric oxide syn-thase and neuronal vulnerability in Parkinson's disease. Neuroscience 72: 355–363.
   PubMed Web of Science ®Google Scholar
• Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA, Agid Y, Hirsch EC (1997). Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson dis-ease. Proc Nail Acad Sci USA 94: 7531–7536.
   PubMed Web of Science ®Google Scholar
• Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, Agid Y, Dugas B, Hirsch EC (1999). FceRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 19: 3440–3447.
   PubMed Web of Science ®Google Scholar
• Kaufmann VVE, Worley PF, Pegg J, Bremer M, Isakson P (1996). COX-2, a synaptically induced enzyme, is ex-pressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Nail Acad Sci USA 93: 2317–2321.
   PubMed Web of Science ®Google Scholar
• Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS (2000). Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20: 6309–6316.
   PubMed Web of Science ®Google Scholar
• Knott C, Stern G, Wilkin GP (2000). Inflammatory regu-lators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 16: 724–739.
   PubMed Web of Science ®Google Scholar
• Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Czlonkowski A, Czlonkowska A (1998). Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharma-cology 39: 167–180.
   PubMed Web of Science ®Google Scholar
• Kopin IJ, Markey SP (1988). MPTP toxicity: implication for research in Parkinson's disease. Annu Rev Neurosci 11: 81–96.
   PubMed Web of Science ®Google Scholar
• Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P (2000). Neurodegeneration prevented by lentiviral vec-tor delivery of GDNF in primate models of Parkinson's disease. Science 290: 767–773.
   PubMed Web of Science ®Google Scholar
• Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, Cochran EJ, Mufson EJ, Penn R, Goetz CG, Comella CD (1999). Clinicopathological findings fol-lowing intraventricular glial-derived neurotrophic fac-tor treatment in a patient with Parkinson's disease. Ann Neurol 46: 419–424.
   PubMed Web of Science ®Google Scholar
• Langston JW, Ballard P, Irwin 1(1983). Chronic parkinson-ism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980.
   Google Scholar
• Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D (1999). Evidence of active nerve cell degen-eration in the substantia nigra of humans years af-ter 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine expo-sure. Ann Neurol 46: 598–605.
   Google Scholar
• Langston JW, Irwin I (1986). MPTP: current concepts and controversies. Clin Neuropharmacol 9: 485–507.
   PubMed Web of Science ®Google Scholar
• Lawson LJ, Perry VH, Dri P, Gordon S (1990). Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39: 151–170.
   PubMed Web of Science ®Google Scholar
• Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S (1999). Inducible nitric oxide syn-thase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5: 1403–1409.
   PubMed Web of Science ®Google Scholar
• Liu B, Jiang JW, Wilson BC, Du L, Yang SN, Wang JY, Wu GC, Cao XD, Hong JS (2000). Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther 295: 125–132.
   PubMed Web of Science ®Google Scholar
• Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH (1995). Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J Neurochem 64: 1645–1654.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988). Reac-tive microglia are positive for HLA-DR in the substan-tia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38: 1285–1291.
   PubMed Web of Science ®Google Scholar
• Mirza B, Hadberg H, Thomsen P, Moos T (2000). The ab-sence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuro-science 95: 425–432.
   Google Scholar
• Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996). Interleukin (IL)-1beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinson-ism and Parkinson's disease. Neurosci Lett 211: 13–16.
   PubMed Web of Science ®Google Scholar
• Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994). Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cere-brospinal fluid from parkinsonian patients. Neurosci Lett 165: 208–210.
   PubMed Web of Science ®Google Scholar
• Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T (2000). Caspase activities and tu-mor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J Neural Transm 107: 335–341.
   PubMed Web of Science ®Google Scholar
• Moratalla R, Quinn B, DeLanney LE, Irwin I, Langston JW, Graybiel AM (1992). Differential vulnerability of pri-mate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methy1-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 89: 3859–3863.
   Google Scholar
• Muthane U, Ramsay KA, Jiang H, Jackson-Lewis V, Donaldson D, Fernando S, Ferreira M, Przedborski S (1994). Differences in nigral neuron number and sensi-tivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/b1 and CD-1 mice. Exp Neurol 126: 195–204.
   Google Scholar
• Nathan C, Xie QW (1994). Regulation of biosynthesis of nitric oxide. J Biol Chem 269: 13725–13728.
   PubMed Web of Science ®Google Scholar
• O'Banion MK (1999). Cyclooxygenase-2: molecular biol-ogy, pharmacology, and neurobiology. Grit Rev Neuro-bio113: 45–82.
   Google Scholar
• O'Callaghan JP, Miller DB, Reinhard JF (1990). Characteri-zation of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methy1-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res 521: 73–80.
   PubMed Web of Science ®Google Scholar
• Pennathur S, Jackson-Lewis V, Przedborski S, Heinecke JW (1999). Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine and 0,0 '-dityrosine in brain tissue of MPTP-treated mice, a model of oxidative stress in Parkinson's disease. J Biol Chem 274: 34621–34628.
   PubMed Web of Science ®Google Scholar
• Przedborski S, Chen Q, Vila M, Giasson BI, Djaldatti R, Vukosavic S, Souza JM, Jackson-Lewis V, Lee VM, Ischiropoulos H (2001a). Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-pheny1-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Neurochem 76: 637–640.
   PubMed Web of Science ®Google Scholar
• Przedborski S, Jackson-Lewis V (2000). ROS and Parkinson's disease: a view to a kill. In: Free rad-icals in brain pathophysiology. Poli G, Cadenas E, Packer L (eds). Marcel Dekker: New York, pp 273–290.
   Google Scholar
• Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G (2000a). The parkinsonian toxin MPTP: action and mechanism. Rest or Neurol Neu-rosci 16: 135–142.
   PubMed Web of Science ®Google Scholar
• Przedborski S, Jackson-Lewis V, Naini A, Jakowec M, Petzinger, G, Miller R, Akram M (2001b). The parkinsonian toxin 1-methy1-4-pheny1-1,2,3,6-tetra-hydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76: 1265–1274.
   PubMed Web of Science ®Google Scholar
• Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM (1996). Role of neu-ronal nitric oxide in MPTP (1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine)-induced dopaminergic neurotoxic-ity. Proc Natl Acad Sci USA 93: 4565–4571.
   PubMed Web of Science ®Google Scholar
• Przedborski S, Vila M (2001). MPTP: A review of its mecha-nisms of neurotoxicity. Clinical Neuroscience Research 1: 407–418.
   Web of Science ®Google Scholar
• Przedborski S, Vila M, Jackson-Lewis V, Dawson TM (2000b). Reply: a new look at the pathogenesis of Parkinson's disease. Trends Pharmacol Sci 21: 165.
   Google Scholar
• Seibert K, Masferrer J, Zhang Y, Gregory S, Olson G, Hauser S, Leahy K, Perkins W, Isakson P (1995). Mediation of in-flammation by cyclooxygenase-2. Agents Actions Suppl 46: 41–50.
   Google Scholar
• Seniuk NA, Tatton WG, Greenwood CE (1990). Dose-dependent destruction of the coeruleus-cortical and nigral- striatal projections by MPTP. Brain Res 527: 7–20.
   Google Scholar
• Sheng JG, Shirabe S, Nishiyama N, Schwartz JP (1993). Al-terations in striatal glial fibrillary acidic protein expres-sion in response to 6-hydroxydopamine-induced dener-vation. Exp Brain Res 95: 450–456.
   PubMed Web of Science ®Google Scholar
• Snow BJ, Vingerhoets FJ, Langston JW, Tetrud JW, Sossi V, Calne DB (2000). Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiatry 68: 313–316.
   PubMedGoogle Scholar
• Sortwell CE, Daley BF, Pitzer MR, McGuire SO, Sladek JR, Collier TJ (2000). Oligodendrocyte-type 2 astrocyte-derived trophic factors increase survival of developing dopamine neurons through the inhibition of apoptotic cell death. J Comp Neurol 426: 143–153.
   PubMed Web of Science ®Google Scholar
• Teismann P, Ferger B (2001). Inhibition of the cyclooxyge-nase isoenzymes COX-1 and COX-2 provide neuropro-tection in the MPTP-mouse model of Parkinson's dis-ease. Synapse 39: 167–174.
   PubMed Web of Science ®Google Scholar
• Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S (2001). Bax ablation prevents dopaminergic neu-rodegeneration in the 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci USA 98: 2837–2842.
   PubMed Web of Science ®Google Scholar
• Vingerhoets FJG, Snow BJ, Tetrud JW, Langston JW, Schulzer M, Calne DB (1994). Positron emission to-mographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 36: 765–770.
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H (2000). NACP/alpha-synuclein-positive fil-amentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol (Berl) 99: 14–20.
   Google Scholar
• Wilkin GP, Knott C (1999). Glia: a curtain raiser. Adv Neurol 80: 3–7.
   Google Scholar
• Xia Y, Zweier JL (1997). Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci USA 94: 6954–6958.
   PubMed Web of Science ®Google Scholar